Leaders in flow cytometry tools collaborate to deliver cloud data management capabilities and streamline experimental execution
ASHLAND, Ore and FRANKLIN LAKES, N.J., June 13, 2017 ─ FlowJo, LLC, a life science informatics and data analysis company with 20 years of experience in software for analyzing single-cell data, and global medical technology company, BD (Becton, Dickinson and Company) (NYSE:BDX), announced today that they have established a strategic relationship to catalyse the coordination of resources, people and data for the research market.
Under the agreement, the companies are collaborating to offer the cloud-based platform, FlowJo Envoy, with BD FACSymphony™, a cell analyzer enabling the simultaneous measurement of up to 50 different characteristics of a single cell.* The combination will enable researchers to improve their workflow, collaborations, store their data in the cloud and share single-cell analysis data in real-time.
“After speaking with scientific resource laboratory leaders about their frustrations with coordinating experiments using email threads and social media, we are excited to bring together the BD FACSymphony cell analyzer and FlowJo Envoy to enable scientists to collaborate, coordinate and execute high-parameter single-cell experiments seamlessly in real-time,” said Michael Stadnisky, Ph.D, CEO of FlowJo, LLC.
FlowJo Envoy offers a platform enabling researchers to create and edit a workflow, select instruments for each step, assign steps to collaborators, and upload data and all associated files. Everything is searchable and organised according to the projects and studies the lab is undertaking. In addition, it offers rich comment features and subscriptions to workflow updates so that communication about an experiment stays proximal to the details, SOPs, experimental progress and data.
“Modern application containerization has allowed us to rapidly bring to market a cloud-based platform that will help accelerate research and collaborations on high-parameter flow in a scalable and secure platform,” said Seth Duncan, director of Information Systems and Technology at FlowJo, LLC.
FlowJo and BD made the announcement at CYTO 2017, the 32nd Congress of the International Society for Advancement of Cytometry, being held June 10-14 at the Hynes Convention Centre in Boston.
FlowJo Envoy by FlowJo, LLC is available now. For more information about FlowJo Envoy, to request a free trial licence, or to get up-to-date training on single-cell data analysis, visit www.flowjo.com.
* The BD FACSymphony system and FlowJo Envoy are intended for Research Use Only and not for use in diagnostic or therapeutic procedures.
About FlowJo, LLC
FlowJo, LLC is a privately-owned life sciences informatics company in Ashland, Oregon. Based on technology developed at Stanford, the company was founded in 1997 and provides the leading analysis platform for single-cell flow cytometry analysis. Their software innovations enable collaboration, discovery, high-throughput analysis, and data leadership in single-cell biology. For more information, see www.flowjo.com.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.